| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Ann Thorac Surg 2005;80:611-617
© 2005 The Society of Thoracic Surgeons
Departments of Cardiovascular Surgery and Cardiology, Institute of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Japan
Accepted for publication February 9, 2005.
* Address reprint requests to Dr Hiramatsu, Department of Cardiovascular Surgery, University of Tsukuba, 1-1-1 Tennodai, Tsukuba 305-8575, Japan (Email: yuji3{at}md.tsukuba.ac.jp).
BACKGROUND: Neutrophil is a major focus in efforts to ameliorate the systemic inflammatory response associated with cardiopulmonary bypass. Neutrophil elastase is a powerful proteolytic enzyme, and plays a pivotal role in the development of the inflammatory response. This study assesses the inhibitory effects of sivelestat, a highly specific neutrophil elastase inhibitor, on elastase levels, cytokine production, and the functional changes of neutrophils in a simulated extracorporeal circulation model.
METHODS: Simulated recirculation was established by recirculating heparinized (3.75 U/mL) human blood for 120 minutes in an oxygenator and a roller pump circuit with and without 100 µmol/L of sivelestat (n = 7 for each group). Neutrophil elastase and interleukin-8 were measured with an enzyme immunoassay. Neutrophil deformability was evaluated by simulated microcapillaries. The neutrophil F-actin and the expression of CD11b and L-selectin were measured by flow cytometry.
RESULTS: Sivelestat reduced both neutrophil elastase levels (p = 0.0006) and interleukin-8 production (p < 0.0001) at 120 minutes of recirculation. Sivelestat also significantly preserved neutrophil deformability (p = 0.017) and reduced F-actin expression (p = 0.0037). The drug did not modulate the changes of CD11b or L-selectin.
CONCLUSIONS: This study suggests that specific elastase inhibition with sivelestat could be a feasible therapeutic strategy for patients undergoing cardiopulmonary bypass to attenuate neutrophil-derived inflammatory response and organ injuries.
This article has been cited by other articles:
|
|
 |
|
  T. Abe, A. Usui, H. Oshima, T. Akita, and Y. Ueda A pilot randomized study of the neutrophil elastase inhibitor, Sivelestat, in patients undergoing cardiac surgery Interactive CardioVascular and Thoracic Surgery, August 1, 2009; 9(2): 236 - 240. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Ostrowski, M. Kasielski, J. Kordiak, and D. Nowak Elevated resting and agonist-induced whole blood chemiluminescence in patients with active infective endocarditis Interactive CardioVascular and Thoracic Surgery, January 1, 2009; 8(1): 12 - 16. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Morimoto, K. Morimoto, Y. Morimoto, H. Takahashi, M. Asano, M. Matsumori, K. Okada, and Y. Okita Sivelestat attenuates postoperative pulmonary dysfunction after total arch replacement under deep hypothermia Eur. J. Cardiothorac. Surg., October 1, 2008; 34(4): 798 - 804. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Ando, T. Murai, and Y. Takahashi The effect of sivelestat sodium on post-cardiopulmonary bypass acute lung injury in a neonatal piglet model Interactive CardioVascular and Thoracic Surgery, October 1, 2008; 7(5): 785 - 788. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Wakayama, I. Fukuda, Y. Suzuki, and N. Kondo Neutrophil Elastase Inhibitor, Sivelestat, Attenuates Acute Lung Injury After Cardiopulmonary Bypass in the Rabbit Endotoxemia Model Ann. Thorac. Surg., January 1, 2007; 83(1): 153 - 160. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |
